Clinical Evidence Gap Analysis is essential before preparing a Clinical Evaluation Report (CER) under EU MDR. Many medical device manufacturers face Notified Body questions because clinical claims, risk management, and available evidence are not properly aligned. Identifying these gaps early can strengthen regulatory submissions and reduce avoidable delays.
Many medical device manufacturers invest considerable time preparing Clinical Evaluation Reports (CERs). They collect literature, review clinical studies, compile PMS data, and prepare scientific conclusions.
Yet, when the technical documentation reaches Notified Body review, important evidence gaps may become apparent.
The problem is not always a lack of clinical data.
Sometimes, the available evidence simply does not answer the right regulatory questions.
This is why Clinical Evidence Gap Analysis should begin before CER preparation, not after a Notified Body raises deficiencies.
Why a Complete CER Can Still Have Weak Evidence
A CER may contain extensive literature and clinical data, but document volume does not establish evidence sufficiency.
For example, a medical device manufacturer may claim long-term safety based on only 12 months of clinical follow-up.
Or a product may claim reduced postoperative infections based primarily on laboratory antibacterial testing.
Both situations raise important questions about whether the evidence actually supports the clinical claim.
Under EU MDR, clinical evaluation should establish a scientifically justified relationship between the device’s intended purpose, clinical benefits, safety, performance, and available evidence.
A strong CER is not about how much evidence you collect. It is about whether you have the right evidence.
What Is Clinical Evidence Gap Analysis?
Clinical Evidence Gap Analysis is a structured process used to identify the difference between the clinical evidence required and the evidence currently available.
It helps manufacturers determine whether clinical claims are adequately supported, whether relevant clinical risks have been addressed, and whether additional evidence generation is necessary.
The process connects the intended purpose, clinical claims, clinical risks, State of the Art, available clinical data, and remaining uncertainties.
Rather than discovering problems during CER drafting, manufacturers can identify them at the planning stage.
Where Do Clinical Evidence Gaps Usually Occur?
1. Clinical Claims Without Sufficient Evidence
A device may demonstrate technical performance but lack adequate evidence supporting its claimed clinical benefits.
For example, demonstrating antibacterial properties in laboratory testing does not automatically prove reduced infection rates in patients.
Every important clinical claim should be mapped to the evidence needed to support it.
2. Weak Device-Specific Clinical Data
A manufacturer may have many published articles about similar devices but limited evidence for the actual device under evaluation.
Evidence from similar devices can provide useful clinical context, but it is not automatically equivalent-device evidence under EU MDR.
The relevance, quality, and applicability of each source must be established.
3. Clinical Risks Not Connected to Evidence
Risk management documentation may identify important risks such as infection, bleeding, tissue injury, device migration, or long-term device failure.
However, the CER must also consider whether available clinical evidence adequately supports the acceptability of clinically relevant residual risks.
When clinical evaluation and risk management operate separately, gaps can remain undetected.
4. Inadequate Long-Term Follow-Up
Short-term clinical results may demonstrate early safety and performance.
However, they may not adequately support claims involving long-term durability, implant survivorship, or sustained clinical benefit.
Manufacturers must ensure that the duration of follow-up matches the clinical questions being evaluated.
5. Generic PMCF Planning
Post-Market Clinical Follow-up (PMCF) should address meaningful uncertainties remaining after clinical evaluation.
A generic PMCF plan may not provide the data needed to close a specific clinical evidence gap.
For example, if long-term device durability remains uncertain, targeted follow-up or registry-based evidence may be more appropriate than a general customer survey.
How to Identify Clinical Evidence Gaps Before Writing a CER
Manufacturers should begin with a structured assessment.
Step 1: Define the device and intended purpose. Establish the exact device version, intended population, clinical application, and conditions of use.
Step 2: Identify clinical claims. Review the IFU, labels, technical documentation, website, and promotional materials.
Step 3: Connect clinical risks. Determine which residual risks require supporting clinical evidence.
Step 4: Establish SOTA benchmarks. Define the clinical safety and performance expectations against which the device will be evaluated.
Step 5: Review available evidence. Examine clinical investigations, published literature, PMS, PMCF, registries, and other relevant sources.
Step 6: Appraise evidence quality. Evaluate study design, relevance, sample size, endpoints, follow-up, limitations, and potential bias.
Step 7: Prioritize evidence gaps. Identify critical, high, moderate, and low gaps based on their potential effect on the evidence conclusions.
Step 8: Develop an evidence strategy. Determine whether additional literature, claim modification, retrospective PMCF, prospective PMCF, or clinical investigation is appropriate.
This approach provides a scientific foundation for CER development.
Does Every Clinical Evidence Gap Require a New Clinical Study?
No. And this is one of the most important decisions manufacturers must make.
Not every gap requires a new prospective clinical investigation.
Sometimes, additional literature analysis may address the missing information.
For devices already used clinically, retrospective data or structured PMCF may help answer unresolved questions.
In other cases, manufacturers may need to reconsider a clinical claim that extends beyond the available evidence.
A new clinical investigation may be necessary when important clinical uncertainties cannot be adequately resolved using existing evidence.
The appropriate strategy depends on the device, its intended purpose, risk profile, regulatory requirements, and the nature of the missing evidence.
The objective is not to conduct more studies. It is to generate the evidence that is actually needed.
Why Clinical Evidence Gap Analysis Matters for Notified Body Readiness
Identifying evidence gaps before submission allows manufacturers to understand weaknesses in their clinical evaluation strategy.
It also helps create stronger alignment between the CER, Risk Management File, Clinical Evaluation Plan, PMS, PMCF, and benefit-risk assessment.
When manufacturers understand the available evidence and its limitations, they can prepare more transparent and scientifically defensible conclusions.
This can reduce avoidable regulatory questions, repeated documentation revisions, and unnecessary evidence-generation expenditure.
How Bioexcel Can Help
At Bioexcel Lifesciences & Research LLP, we help medical device manufacturers identify clinical evidence gaps before CER preparation, EU MDR submission, and Notified Body review.
Our Clinical Evidence Gap Assessment services cover intended purpose, clinical claims, device-specific evidence, literature, State of the Art, equivalence, risk management, PMS, PMCF, and benefit-risk evaluation.
Based on the assessment, Bioexcel can provide a structured Clinical Evidence Gap Matrix, prioritized findings, recommended evidence strategy, and a roadmap for CER preparation or additional clinical evidence generation.
We help manufacturers make informed decisions about which gaps need attention and which evidence-generation activities are appropriate.
Final Thoughts
A Clinical Evaluation Report should not be the place where a manufacturer first discovers missing clinical evidence.
That discovery should happen earlier.
Before drafting your next CER, ask:
Do we have sufficient clinical evidence to support what our device actually claims?
If the answer is uncertain, Clinical Evidence Gap Analysis is the right place to begin.
Don’t wait for Notified Body questions to reveal your evidence gaps.
Need Help With Something Like This?
Talk to our team about the clinical, regulatory or scientific evidence your program needs.
Discuss Your Requirement